Kos Pharmaceuticals Agrees to Take on Jerini's Icatibant in North America
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 66 (Table of Contents)
Published: 1 Dec-2005
DOI: 10.3833/pdr.v2005.i66.585 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Just days after going public, Jerini has succeeded in its quest to find a North American partner for its niche Phase III drug, by signing an exclusive licensing deal with Kos Life Sciences, a subsidiary of the US speciality pharma company, Kos Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS